JPRN-UMIN000034502
Completed
未知
An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial' - W-JHS NHL02-A study
Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu0 sites20 target enrollmentOctober 15, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Nothing particular
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
W-JHS NHL02-A studyPeripheral T-cell lymphoma (including extranodal NK/T-cell lymphoma)JPRN-jRCT1071210120Akashi Koichi20
Completed
Not Applicable
A retrospective study to explore the efficacy and safety of FOLFOX therapy and FOLFOX with radiation in esophageal squamous cell carcinomaesophageal squamous cell carcinomaJPRN-UMIN000047501ational Hospital Organization Nagoya Medical Center, Department of Medical Oncology143
Completed
Phase 3
A Follow-up Study of the Efficacy of a Complementary Medicine Formulation in Primary HypercholesterolemiaPrimary hypercholesteremiaDiet and Nutrition - Other diet and nutrition disordersACTRN12605000257662Pathways30
Active, not recruiting
Phase 2
A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.Colorectal CancerJPRN-jRCTs071190003Oki Eiji35
Recruiting
Not Applicable
on-interventional study for the analysis of efficacy and safety of EstraCept(R) 280 mg (Estramustin phosphate) at patients with castration resistant prostate cancer in three therapy situationsC61Malignant neoplasm of prostateDRKS00003204PharmaCept GmbH300